When Botulinum Toxin Stops Lasting — Resistance, or Dose and Interval?

Three-Line Summary

• True resistance from neutralizing antibodies is rare. A large meta-analysis reported antibody formation at around 0.3%, and among people with confirmed antibodies, far fewer actually had no response.
• The common reason results feel weaker is not the product but dosing units, treatment interval, injection sites and touch-up habits. How and how often you use it weighs more than what you use.
• The conditions that genuinely raise the risk of antibody formation are fairly clear: repeated intervals shorter than three months, a touch-up within three weeks of the first session, a large cumulative dose, and imprecise injection and handling. Shortening the interval out of fear of resistance is what creates those conditions.

What the Word Resistance Actually Points To

Resistance means a reduced or lost biological response to a particular drug or toxin. It mostly refers to effect falling away gradually over repeated or long-term use. With botulinum toxin, that state is called secondary non-response. It describes a response that worked well at first and then faded over time.

Secondary non-response has four branches

• An immune response (neutralizing antibody formation) — the body makes antibodies to block the toxin.
• Errors in handling the drug — problems arising in storage or reconstitution.
• Progression of the condition — the problem being treated has itself changed, so the same treatment no longer covers it.
• A change in patient factors — current medications, infection, shifts in general condition.

One point is worth noticing here. Just one of the four is an immune problem, and the other three have nothing to do with antibodies. Yet in clinic, the moment someone says the response has dropped, the word resistance follows almost automatically. The conclusion arrives before the causes have been narrowed at all.

Everyday resistance and medical resistance cover different ground

This gap is where the confusion starts. In everyday use, resistance covers any situation where something seems to work less well than before. People reach for the same word when the duration shortens, when the two sides feel uneven, and when the change was smaller than expected.

Medically, resistance means a far narrower state. It is a body that genuinely no longer responds to the drug, and within that, antibodies account for only part. Because the same word covers different ground, an explanation that this is not resistance is sometimes heard as a claim that the effect has not dropped.

So the question this article is about is not whether the effect has dropped. It is why it dropped. The sense that it is not what it used to be is usually accurate; what needs to change is where you look for the reason.

What neutralizing antibodies are

Neutralizing antibodies (NAbs) are antibodies the immune system produces to block a toxin that has entered the body. They bind to the active site of the toxin and keep it from acting at the neuromuscular junction. The treatment effect then disappears completely or in part.

Factors known to drive antibody formation include repeated high-dose administration, short treatment intervals and the characteristics of the formulation. The formulation does occupy one of those places. But it is one of three, and the other two are not about the product — they are about how the treatment was planned.

The Complexing Protein Hypothesis — How Far the Evidence Goes

Botulinum toxin type A is a toxin produced by the bacterium Clostridium botulinum. In the early days it was used for wrinkles; more recently the range has widened into fine lines, redness and sebum control.

Structurally it consists of a 150 kDa core neurotoxin wrapped in roughly 900 kDa of complexing proteins. Those complexing proteins divide again into hemagglutinin (HA) and non-toxic non-hemagglutinin (NTNHA) proteins.

It is well established that the core neurotoxin is what carries the treatment effect. And research suggested that the complexing proteins attached to it can trigger an immune response without contributing to that effect. This is what is known as the complexing protein hypothesis.

The three routes the hypothesis proposed

• An adjuvant role — the explanation that complexing proteins activate dendritic cells.
• A higher antigenic protein load — the explanation that as the sheer amount of protein entering the body rises, so does the risk of antibody formation.
• Stimulation of inflammatory cytokine pathways — the explanation that pathways such as IL-6 are stimulated.

On the strength of this hypothesis, formulations split into two lines: those with the complexing proteins removed, leaving the core neurotoxin alone, and those that include them. This is where the familiar framing of regular botulinum toxin versus resistance-free botulinum toxin came from.

Up to here, the story is easy to follow. If part of the product stimulates the immune system without contributing to the effect, taking it out sounds intuitively persuasive. That is also why most people accept the explanation straight away when they hear it in consultation.

A hypothesis and a clinical result sit on different levels

The trouble starts after that. What matters is that this hypothesis does not always translate into clinical failure. That antibodies can form and that those antibodies actually end the effect are two different statements. The first is an immunological observation and the second a clinical outcome, and the two levels frequently merge into one in conversation.

In practice, antibodies themselves are very rare, and treatment interval, dose and targeting are far more common reasons behind a dropped response. That is not to say the hypothesis is wrong. It means the share of the whole picture it explains is smaller than people assume.

For the same reason, the phrase resistance-free botulinum toxin is not accurate either. Formulations designed in the direction of provoking fewer antibodies exist, but calling something a formulation that cannot cause resistance runs ahead of the evidence. The wording itself is not the real problem; the problem is the decision to shorten the interval because of it.

What Numbers the Research Actually Shows

Conclusions on this subject vary between studies, so reading one number on its own invites misunderstanding. Let us put sources that point in different directions side by side.

0.3% against 0.3% — the formulation gap was smaller than expected

There is a particular reason the 2022 source matters. That review was a comprehensive review that received no industry funding. Four of the five systematic studies published before it were industry-funded, and a tendency to favour the sponsor product was pointed out.

Once you know this, it goes some way to explaining why conclusions differ between studies. Data showing lower immunogenicity for a particular formulation does exist, but research finding no difference is not scarce either. The point is that sources with sponsorship ties call for care in interpretation, not that one side or the other is wrong.

And having antibodies does not mean it stops working

Look again at the numbers from the 2023 meta-analysis. Of around 30,000 people, 90 had confirmed neutralizing antibodies, and among them the cases with no treatment response numbered 5. There is a considerable distance between having antibodies and losing the effect.

For aesthetic treatment with small amounts, the odds fall further. The rate of antibody formation reported in that range is around 0.2-0.4%. Which means most people who come in worried about resistance are in fact outside that probability.

Rare, though, is not the same as absent. Three in a thousand is a number you can certainly meet in a group that has continued repeat treatment over years. So this is not an argument for ruling immune factors out. It is an argument for placing them later in the order you check. Skip the more common causes at the front and start with the rarest, and the cause usually stays where it was.

So why does it still get filed under the product

Even with numbers like these on record, the idea that resistance means a product problem does not disappear easily. There are reasons for that.

In consultation, botulinum toxin usually gets explained quickly as a handful of options — domestic or imported, a regular formulation or one with the complexing proteins removed. It is a shorthand meant to keep the explanation short, but hearing it repeatedly leaves the impression that the result is decided by which product you pick.

A product is also visible, has a name, and is something you can choose yourself. Treatment interval, cumulative dose and injection sites are invisible and only surface when you go back through the records. Attention moving to the variable that feels controllable is natural enough, but that is a different thing from the share it holds in the result.

Two sentences we hear often

• I will take the resistance-free one no matter what, because it is better — as we saw above, the difference in antibody formation between formulations varies by study, and some sources report no difference at all. The evidence does not gather on one side firmly enough to support a flat claim that one is better.
• I am on the resistance-free one, so it is fine to come more often — this sentence is the riskier of the two. Short intervals and a large cumulative dose are classed as risk factors regardless of formulation. A choice made for reassurance ends up being used as grounds for adding real risk factors.

To put it together: contrary to the common view, resistance is less a matter decided by a single product than the combined result of dose and interval, technique and patient factors. The formulation is one line on that list, and the rest of the list is much longer. That is the heart of this subject.

So What Does Raise the Risk

Resistance to botulinum toxin is not explained by neutralizing antibodies alone. Set out the known triggers and they look like this.

Read the table again and one thing stands out. Nowhere in the four rows is which product you used something that decides the outcome on its own. Formulation characteristics sit inside a list of several factors, and everything else is a question of how it was stored, and where, how much and how often it was injected.

Taking the four branches one at a time

Handling and storage is the area a patient cannot check. Storage temperature, the solution and method used for reconstitution, even the bubbles created by how hard the vial is shaken, all belong here. It is easy to pass over because none of it is visible, but it sits on the first line of the list.

Injection technique is what most directly creates differences in the result. Miss the muscle and the drug goes in while the intended muscle gets less of it. Putting in more than needed, and concentrating in one spot what should have been split, are both classed as risk factors.

Treatment parameters come as a set of three: a treatment interval shorter than three months, a large cumulative dose, and a booster injection going in within three weeks of the first dose. These three often move together, so when one slips, the others tend to slip with it.

Patient factors mix things that are hard to change with things that simply need checking. Individual immune reactivity and constitution are not adjustable, but current medications and infection are items we can confirm in clinic. If things are different from before, it helps to look at whether anything here changed.

That is why, in day-to-day practice, correcting the interval, the dosing units and the injection sites first leads to a result more often than switching product does. How, how often and for whom it is used weighs more than what is used.

Why Short Intervals and Frequent Touch-Ups Are a Problem

Treatment parameters are the row in that table people trip over most often. All the more so because interval and touch-ups are the parts a patient chooses directly.

The immune system responds to repeated stimulation

When the same antigen keeps arriving at short intervals, the immune system gets more chances to recognise it and respond. That is the background to three months or more being quoted as a benchmark. Repeated intervals under three months are classed as a risk factor.

It does not mean one or two short intervals cause a problem straight away. What causes a problem is a short interval becoming a habit.

A touch-up is structurally the same as a booster

An extra injection within three weeks of the first dose becomes, immunologically, much the same pattern as a booster shot. That is why boosters appear as their own entry on the list of risk factors for antibody formation.

Wanting more right away because one side looks like it took less is entirely understandable. But toxin builds up its action over time rather than immediately after injection, so judging early makes a shortfall easy to see. Set the assessment date in advance and judge then, and quite often the extra injection turns out not to be needed at all.

The choice made out of fear of resistance creates the conditions

Here is the most ironic structure in the whole subject. If it feels like the effect is fading fast, you shorten the interval; if it looks short of the mark, you have a touch-up. The result: the interval gets shorter and the cumulative dose gets larger. The entries on the risk-factor list stack up exactly as written.

An action taken out of fear of resistance works in the direction of creating the conditions for it. And if the effect then feels even more lacking, the interval gets shortened again. Breaking that loop comes before changing product.

How to read the number three months

One misunderstanding is worth clearing up here. Three months is a floor you do not go below, not a timetable saying you must be treated every three months. If the effect is still there, leaving a longer gap causes no problem, and in terms of cumulative dose it is the better option.

Writing the next treatment date in the diary in advance and being treated on that day regardless of how things look is not something we recommend. The longer someone continues repeat treatment, the more a habit of judging again at each session whether it is needed now does real work in bringing the total down.

How to think about cumulative dose

If you only treat areas that finish with small amounts, like the forehead, glabella and crow's feet, the burden on the total is not large. For treatments that take a lot, like the trapezius or the calves, and treatments repeated over a wide area like skin botulinum toxin, it is safer to record the dosing units per session alongside the running total and plan from there. That does not make them treatments to avoid. It makes them conditions where the interval has to be kept more clearly.

The Order to Check When the Effect Drops

The order matters. A change of product belongs on the last line of the list, not the first.

• 1. Was the recent interval shorter than three months? — look at whether it was short repeatedly, not once. List the dates of the last few sessions and it usually shows up straight away.
• 2. Have touch-ups become a habit? — if an extra injection within three weeks of the first dose happened at every session, that alone is worth reviewing.
• 3. Were the injection sites right? — even for the same square jaw, the shape, thickness and attachment of the masseter differ from person to person. The same goes for how the forehead and glabellar muscles run. If the site is off, the effect feels weaker regardless of dose.
• 4. Were the dosing units too low? — where a muscle is thick and strong, the same dosing units may not be enough. It may not be that it has stopped working, but that less went in than needed.
• 5. Have your medications or general condition changed? — muscle relaxants, some antibiotics, antiarrhythmics and other drugs involved in neuromuscular transmission, along with infection, belong here.

There is a reason for this order. The first two items are settled by the records alone. List the dates session by session, mark where the touch-ups were, and within a few minutes it becomes clear whether this is a situation that calls for suspecting resistance or simply one where the interval was short. In practice, this is the stage where most cases resolve.

Items 3 and 4 have to be confirmed in person. Muscle shape and thickness are hard to judge from photographs or description, and palpation is what produces a site and a dose matched to the muscle as it is now. This is where we separate too little went in from it is not working. The two feel similar and call for opposite responses.

Item 5 is easy to miss. If the treatment conditions stayed the same and only the result changed, what changed may be on the body side. We check whether any new medication started in the meantime, and whether there was a bout of illness or infection.

If the response still has not recovered after these five have been reviewed and adjusted, that is when a change of formulation is considered. There are reports of people with no response on a formulation containing complexing proteins regaining a response after switching to one with them removed. But in the order, this is the last card, not the first.

Why keeping the order matters is simple. Change only the product and leave the interval and the injection sites as they were, and the same thing can repeat with the new product.

When It Is Not Resistance but Feels Like It Stopped Working

There is another branch, separate from those five. The interval was kept, the site was right, the dose was enough, and still the expected change does not appear. Here the problem may not be the treatment but a mismatch between what the treatment addresses and what the problem now is.

Dynamic lines and settled lines are different

Botulinum toxin is a drug that reduces muscle power. So it works well on dynamic lines that fold when you make an expression. A line etched in even at rest, though, is not a muscle matter alone. Folding of the skin itself and changes in the dermis are involved alongside it.

A good number of the cases where the first few rounds were satisfying and then began to feel short belong here. The area is the same, but the character of the line has changed. The drug has not stopped working.

Checking is not difficult. Relax your expression completely and see whether the line is still there. A line that disappears when you relax sits close to what toxin addresses; a line that stays even then means factors beyond muscle are involved as well. In that case, raising the dose alone tends not to change things as much as you want.

When the layer of the problem has shifted

Someone whose contour was well managed with masseter treatment can find, a few years later, that the same treatment no longer satisfies. What to check here is whether the reason the contour looks less defined is still the volume of the muscle. Over time, laxity of the skin and subcutaneous tissue can come to account for more of it, and in that state raising the toxin dose does not readily produce the change you want.

Without that distinction, the response is aimed at the wrong thing. Raise the dose when laxity is the main reason, and the effect does not change much while the cumulative dose alone grows.

At ABLE Dermatology we separate the layers before choosing the tool in cases like this. Ulthera Prime (high-intensity focused ultrasound) aimed at the SMAS layer, Density (sequential radiofrequency) for tightening across the dermis and subcutis, Onda (microwave) for the volume of the fat layer, Olewave for collagen stimulation alongside calming, and filler to support a hollowed area — we pick the one that matches the layer the cause sits in. Response and duration vary between individuals.

When expectations have grown

Less common, but it does happen. Compared with the state before the first treatment there is a clear difference, yet the point of comparison has quietly moved to the peak moment just after treatment. In this case, aligning what is being compared with what is a better starting point for the conversation than changing the drug.

To sum up: before looking for the cause of a weaker effect in the product, first confirm which layer the problem is in now.

The Order We Follow at ABLE Dermatology

When someone comes in saying botulinum toxin is not what it used to be, we do not open with the product. The items we check come first, and the plan that follows is set by what they show.

• Past treatment history — we lay out the dates and intervals session by session, the areas, the dosing units and whether there were touch-ups. This is the stage where the cause emerges most often.
• Re-checking the injection sites — we confirm the shape, thickness and attachment of the muscle directly, and set the site and depth again to the muscle as it is now.
• Minimum effective dose and split injection — putting in what is needed, divided, in the right places, is the baseline. Raising the dose is a conversation for after the site and layer have been confirmed.
• Standardised handling — storage, reconstitution, the steps that limit bubbles and the injection technique are kept consistent.
• Medications and general condition — we check together for changes in drugs that can act on neuromuscular transmission and in overall condition.

On formulations, this is what we tell people. Both formulations containing complexing proteins and formulations with them removed are available, and where a short interval is unavoidable, or for treatments with a large total or repeated over a wide area, the latter may be put on the table. That, though, does not mean you can be treated more often. The standards for treatment interval and cumulative dose apply the same way regardless of formulation.

And we agree the assessment date first. Rather than judging right after treatment, we look at it together at the set point and adjust then. With that appointment in place, the rush to add an injection during the stretch when it looks lacking becomes less likely. The degree of effect and how long it lasts vary between individuals.

To finish in one sentence: resistance is less a problem of the product than the combined result of dose and interval, technique and patient factors. If resistance is on your mind, we suggest checking the interval, your touch-up habits, and how the injection sites and dosing units are planned, before choosing a formulation.

From Consultation to Treatment

A board-certified dermatologist examines you directly, identifies the layer behind the problem, sets the device and parameters, and then carries out the treatment personally. There is no consultant here to recommend procedures.

Sessions, intervals, maintenance timing and cost are agreed together before the first treatment.